Proto-Oncogene Proteins c-bcl-2
"Proto-Oncogene Proteins c-bcl-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.
| Descriptor ID |
D019253
|
| MeSH Number(s) |
D12.644.360.075.718 D12.776.476.075.718 D12.776.624.664.700.169
|
| Concept/Terms |
Proto-Oncogene Proteins c-bcl-2- Proto-Oncogene Proteins c-bcl-2
- Proto Oncogene Proteins c bcl 2
- c-bcl-2, Proto-Oncogene Proteins
- bcl-2 Proto-Oncogene Proteins
- Proto-Oncogene Proteins, bcl-2
- bcl 2 Proto Oncogene Proteins
- c-bcl-2 Proteins
- c bcl 2 Proteins
B-Cell Leukemia 2 Family Proteins- B-Cell Leukemia 2 Family Proteins
- B Cell Leukemia 2 Family Proteins
- BCL2 Family Proteins
- Family Proteins, BCL2
- Proteins, BCL2 Family
- BCL2 Proteins
- Proteins, BCL2
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-bcl-2".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-bcl-2".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-bcl-2" by people in this website by year, and whether "Proto-Oncogene Proteins c-bcl-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 6 | 6 |
| 1995 | 4 | 12 | 16 |
| 1996 | 11 | 12 | 23 |
| 1997 | 19 | 5 | 24 |
| 1998 | 23 | 12 | 35 |
| 1999 | 14 | 9 | 23 |
| 2000 | 22 | 14 | 36 |
| 2001 | 26 | 13 | 39 |
| 2002 | 28 | 24 | 52 |
| 2003 | 17 | 24 | 41 |
| 2004 | 16 | 27 | 43 |
| 2005 | 7 | 26 | 33 |
| 2006 | 9 | 15 | 24 |
| 2007 | 14 | 17 | 31 |
| 2008 | 15 | 12 | 27 |
| 2009 | 6 | 13 | 19 |
| 2010 | 11 | 20 | 31 |
| 2011 | 14 | 10 | 24 |
| 2012 | 10 | 12 | 22 |
| 2013 | 10 | 8 | 18 |
| 2014 | 4 | 11 | 15 |
| 2015 | 14 | 13 | 27 |
| 2016 | 10 | 11 | 21 |
| 2017 | 8 | 9 | 17 |
| 2018 | 4 | 8 | 12 |
| 2019 | 10 | 7 | 17 |
| 2020 | 5 | 10 | 15 |
| 2021 | 7 | 14 | 21 |
| 2022 | 2 | 17 | 19 |
| 2023 | 2 | 25 | 27 |
| 2024 | 2 | 8 | 10 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-bcl-2" by people in Profiles.
-
Precision medicine in AML: overcoming resistance. Int J Hematol. 2024 Oct; 120(4):439-454.
-
Apoptosis Pathway-Associated Proteins Are Frequently Expressed in Melanoma: A Study of 32 Cases With Focus on Acral Lentiginous Melanoma. Am J Dermatopathol. 2024 Jul 01; 46(7):410-415.
-
Cadherin-11 targeted cell-specific liposomes enabled skin fibrosis treatment by inducing apoptosis. J Control Release. 2024 Jun; 370:110-123.
-
ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells. Oncotarget. 2024 Mar 14; 15:220-231.
-
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123. Leuk Res. 2024 04; 139:107479.
-
Childhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge. Pediatr Dev Pathol. 2024 Jul-Aug; 27(4):348-353.
-
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024 02 13; 8(3):591-602.
-
Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). Blood Cancer J. 2024 02 05; 14(1):25.
-
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. Clin Cancer Res. 2024 02 01; 30(3):498-505.
-
The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research. J Pathol. 2024 03; 262(3):255-270.